ArcticZymes’ Proteinase is a novel heat-labile enzyme easily inactivated after use. Gentle inactivation of the enzyme enables broader compatibility in the development of kits and products serving the In Vitro Diagnostic (IVD) and molecular research market segments.
In developing the Proteinase, ArcticZymes worked with collaborators and customers to demonstrate its key benefits in streamlining workflows in research and product development. In particular, ArcticZymes has collaborated with Associate Professor Anders Ståhlberg, a leading authority in single-cell biology and liquid biopsies at the Sahlgrenska Cancer Center in Gothenburg. Ståhlbergs’ lab demonstrated the utility of ArcticZymes Proteinase to solve technical challenges in the isolation of low abundance DNA samples from precious biopsies or biological samples, prior to DNA analysis by PCR and Next Generation Sequencing.
“The properties of ArcticZymes’ Proteinase open up new possibilities to analyze nucleic acids in ways that has not been possible before. Currently, we are exploring a number of applications in the areas of liquid biopsy and single-cell analysis’’ says A. Ståhlberg.
The new enzyme is supported by intellectual property, which ArcticZymes will convey to its customers. By adopting the enzyme, customers can take advantage of its benefits to improve existing kits and in the development of new products or technologies.
With respect to potential, the new enzyme will open ArcticZymes ability to penetrate the liquid biopsy and sample preparation markets within our existing customer base as well as new IVD customers we are not reaching today. The technical advantages ArcticZymes Proteinase offers will resonant well with IVD companies developing non-invasive tests based on cancer biomarkers. As with any new enzyme launch, it will take 1-4 years for our customers to commercialize their technologies or IVD assays containing the enzyme. Longer-term we can expect Proteinase sales similar to our leading products today. The incremental addition of new synergist products to ArcticZymes portfolio will continue to increase our relevance to customers across the market segments we serve.
“ArcticZymes Proteinase is a new class of enzyme for the company and provides synergy with our other enzyme product offerings. The enzyme enables ArcticZymes to provide a new component to the liquid biopsy and sample preparation market. We are excited to offer another unique innovation and look forward to supporting our customers in exploiting the enzymes unique features in their product developments.” says Jethro Holter, Managing Director ArcticZymes, AS.
“The hallmark of the enzyme is salt tolerance. Most nucleases in the molecular toolbox can tolerate sodium chloride up to about 150 mM (depending on other conditions), but other enzymes like salt active nuclease (SAN) in fact have optimal activity at around 500 mM sodium chloride.”
ArcticZymes today announced the expansion of their polymerase portfolio. The IsoPol™ SD⁺ and IsoPol™ BST⁺ deliver low temperature isothermal polymerases, one with increased strand displacement, and the second an improvement over existing Bacillus stearothermophilus available today.
IsoPol™ SD+ is a DNA polymerase with stronger strand displacement activity, and higher salt tolerance compared to ArcticZymes first IsoPolTM polymerase. IsoPol™ SD+ is available for shipment during January 2018.
IsoPol™ Bst+ is a polymerase with stronger strand displacement and higher salt tolerance compared to the thermostable Bst wild type. IsoPol™ SD+ will be available for shipment during first quarter 2018.
ArcticZymes strategy has been to innovate the next generation of polymerases to serve the unmet demands necessary to facilitate the development of novel molecular technologies. In combination with a variety of attractive features engineered into the enzymes ArcticZymes is able to offer a diverse range of unique IsoPol™ polymerases to its commercial partners and end users.
For more details about the IsoPol™ polymerase portfolio visit our technology page.
Disclaimer: These products are intended for further manufacturing use or research use only. Certain applications of ArcticZymes AS products may require licenses from others. It is the expressed duty of any receiver of ArcticZymes AS products to acquire such licenses, if necessary. To the extent allowed by law, ArcticZymes AS will not be liable for damages, whether direct, indirect, incidental, or consequential in connection with or arising from this document, including the use of it. ArcticZymes AS products may be covered by pending or issued patents, designs or design applications and/or trademarks or trademark applications or any other registered or unregistered Intellectual Property Right.
ArcticZymes has today launched its SAN HQ ELISA immunoassay product which is targeted towards the bio-manufacturing market.
ArcticZymes business has largely focused on serving the molecular biology and diagnostics markets. Serving the bio-manufacturing market is a new direction for ArcticZymes in its efforts to expand into other relevant segments. Through its unique products, ArcticZymes enter this market with a strong value proposition to companies and institutes who are manufacturing viruses for gene therapy, vaccines, proteins and other bio reagents.
In combination with the SAN HQ enzyme released earlier this year, the new immunoassay product provides a complete solution for the critical elimination of DNA contamination during bio-manufacturing. Compared to current technologies used in the market, ArcticZymes innovative solution offers bio-manufacturers the opportunity to better streamline their manufacturing processes and benefit from cost savings. This launch is in line with ArcticZymes strategic initiatives presented at the Capital Markets Day and will be a key factor in achieving both short and long-term sales growth.
“We are excited to evolve our business into new markets where our unique technologies can have a major impact. The bio-manufacturing market opens up a great opportunity for ArcticZymes to engage and grow business with a new customer base” says Jethro Holter, Managing Director, ArcticZymes AS.